Leap Therapeutics initiates Part B of the DeFianCe study of DKN-01

Leap Therapeutics announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study. The study evaluates Leap’s anti-Dickkopf-1 antibody, DKN-01, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced CRC.